v3.25.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2024
Jun. 30, 2024
Current assets:    
Cash and cash equivalents $ 177,549 $ 151,791
Short-term available-for-sale investments 0 1,072
Accounts receivable, less allowance for doubtful accounts of $4,904 and $4,386, respectively 217,940 241,394
Inventories 188,373 179,731
Current assets held-for-sale 1,047 9,773
Other current assets 49,731 33,658
Total current assets 634,640 617,419
Property and equipment, net 249,753 251,154
Right-of-use assets 85,383 91,285
Goodwill 964,607 972,663
Intangible assets, net 461,051 507,081
Other assets 274,990 264,265
Total assets 2,670,424 2,703,867
Current liabilities:    
Trade accounts payable 33,120 37,968
Salaries, wages and related accruals 53,594 49,818
Accrued expenses 27,543 24,886
Contract liabilities 27,715 27,930
Income taxes payable 3,141 3,706
Operating lease liabilities - current 13,511 12,920
Other current liabilities 2,632 2,151
Total current liabilities 161,256 159,379
Deferred income taxes 37,723 55,863
Long-term debt obligations 300,000 319,000
Operating lease liabilities 81,616 87,618
Other long-term liabilities 11,337 13,157
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,915,999 and 158,216,258 respectively 1,579 1,582
Additional paid-in capital 875,864 820,337
Retained earnings 1,286,699 1,325,247
Accumulated other comprehensive loss (85,650) (78,316)
Total Bio-Techne's shareholders' equity 2,078,492 2,068,850
Total liabilities and shareholders' equity $ 2,670,424 $ 2,703,867

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL